Size of elderly populations in COVID-19 vaccine trials: Data Byte

As controversy swirls around a German paper that claimed AstraZeneca’s COVID-19 vaccine is not efficacious in elderly participants, what is clear is that the pharma and partner University of Oxford didn’t test the vaccine in nearly as many older participants as mRNA vaccine front-runners Moderna and Pfizer/BioNTech.

Partners Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) enrolled 37,706 participants in the Phase III trial of Comirnaty, of which 15,921 (42%) were over 55 years old. And 7,512 (25%) of the 30,351 participants in the Phase III trial of Moderna COVID-19 Vaccine (mRNA-1273) from Moderna Inc. (NASDAQ:MRNA) were over 65 years old...